Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009

다국어 초록 (Multilingual Abstract)

This study was performed to evaluate the utilization and outcomes of palivizumab in high risk children born prematurely with chronic lung disease (CLD). A retrospective review of 128 patients was conducted from September 2004 to March 2009 at the Ajou University Hospital. All patients were diagnosed with CLD, were born at ≤35 weeks of gestation, were <2 yr old at the onset of respiratory syncytial virus (RSV) season, and had received medical therapy within six months prior to the RSV season. Fifty-three patients did not receive palivizumab prophylaxis and 75patients received at least one dose of palivizumab. There were no statistically significant differences between the patients with and without palivizumab prophylaxis with regard to demographic characteristics and risk factors for RSV infection. There were no systemic adverse responses. Compliance with the course of prophylaxis was 92.2%. Hospitalization associated with RSV occurred in 12 cases (22.6%) in the group without prophylaxis and in three cases (4.0%) with prophylaxis. Palivizumab prophylaxis significantly reduced the frequency of RSV-related hospitalization in preterm children with CLD. This is the first retrospective review of palivizumab prophylaxis in Korea. Palivizumab is effective and well tolerated in high risk prematurely born children.

참고문헌 (Reference)

1 이은아, "미숙아에서 RS 바이러스 감염으로 인한 재입원 빈도와 관련 인자" 대한소아과학회 47 (47): 510-514, 2004

2 Loughlin GM, "The cell biology of acute childhood respiratory disease: therapeutic implications" 53 : 929-959, 2006

3 Choi EH, "The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005" 43 : 585-592, 2006

4 Holman RC, "Risk factors for bronchiolitis-associated deaths among infants in the United States" 22 : 483-490, 2003

5 American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn, "Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections" 112 : 1442-1446, 2003

6 Simoes EA, "Respiratory syncytial virus infection" 354 : 847-852, 1999

7 Hall CB, "Respiratory syncytial virus and parainfluenza virus" 344 : 1917-1928, 2001

8 American Academy of Pediatrics, "Red-book: 2006 report of the committee on infectious disease. 27th ed" American Academy of Pediatrics 2006

9 Boyce TG, "Rates of hospitalization for respiratory syncytial virus infection among children in medicaid" 137 : 865-870, 2000

10 Frogel M, "Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry" 28 : 511-517, 2008

11 Thorburn K, "Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection" 94 : 99-103, 2009

12 The Impact-RSV Study Group, "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants" 102 : 531-537, 1998

13 Palivizumab Outcomes Registry Study Group, "Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry" 35 : 484-489, 2003

14 Oh PI, "Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes" 21 : 512-518, 2002

15 Thompson WW, "Mortality associated with influenza and respiratory syncytial virus in the United States" 289 : 179-186, 2003

16 Sampalis JS, "Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants" 143 (143): 150-156, 2003

17 Saji BT, "Indications, efficacy and Safety of Anti-RS Virus Monoclonal Antibody Palivizumab (Synagis) for Pediatric Patients With Congenital Heart Diseases" 11 : 149-150, 2007

18 Kim MR, "Epidemiology of acute viral respiratory tract infections in Korean children" 41 : 152-158, 2000

19 Sorrentino M, "Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group" 19 : 1068-1071, 2000

20 American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis, "Diagnosis and management of bronchiolitis" 118 : 1774-1793, 2006

21 Ahn KM, "Clinical characteristics of acute viral lower respiratory tract infections in hospitalized children in Seoul, 1996-1998" 14 : 405-411, 1999

22 Kim YK, "Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005" 40 : 946-953, 2008

23 Jobe AH, "Bronchopulmonary dysplasia" 163 : 1723-1729, 2001

24 Centers for Disease Control and Prevention (CDC), "Brief report: respiratory syncytial virus activity-United States, 2005-2006" 55 : 1277-1279, 2006

25 Denny FW, "Acute lower respiratory tract infections in nonhospitalized children" 108 : 635-646, 1986